rs267606977
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_016203.4(PRKAG2):c.1589A>G(p.His530Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
PRKAG2
NM_016203.4 missense
NM_016203.4 missense
Scores
11
8
1
Clinical Significance
Conservation
PhyloP100: 7.81
Genes affected
PRKAG2 (HGNC:9386): (protein kinase AMP-activated non-catalytic subunit gamma 2) AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family. Mutations in this gene have been associated with Wolff-Parkinson-White syndrome, familial hypertrophic cardiomyopathy, and glycogen storage disease of the heart. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jan 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a binding_site (size 0) in uniprot entity AAKG2_HUMAN
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.968
PP5
Variant 7-151560613-T-C is Pathogenic according to our data. Variant chr7-151560613-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 6854.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRKAG2 | NM_016203.4 | c.1589A>G | p.His530Arg | missense_variant | 15/16 | ENST00000287878.9 | NP_057287.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PRKAG2 | ENST00000287878.9 | c.1589A>G | p.His530Arg | missense_variant | 15/16 | 1 | NM_016203.4 | ENSP00000287878 | P3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 08, 2012 | p.His530Arg (CAT>CGT:c.1598 A>G in exon 15 of the PRKAG2 gene (NM_016203.3) The His530Arg mutation in the PRKAG2 gene has been reported previously in one individual with childhood-onset HCM, and this mutation was absent from >1,000 control alleles. In addition, the NHLBI ESP Exome Variant Server reports His530Arg was not observed in approximately 5,000 samples from individuals of European and African American backgrounds, indicating it is not a common benign variant in these populations. Although His530Arg results in a conservative substitution of one positively charged amino acid for another, the His530 residue is conserved across species. Mutations in a neighboring codon (Arg531Gln, Arg531Gly) have also been reported in association with PRKAG2-related phenotypes, supporting the functional importance of this region of the protein. In summary, the presence of His530Arg in the PRKAG2 gene is consistent with a diagnosis of a PRKAG2-related cardiomyopathy and/or Wolff-Parkinson-White (WPW) syndrome. The variant is found in HCM panel(s). - |
Hypertrophic cardiomyopathy 6 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2008 | - - |
Hypertrophic cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego | Feb 07, 2018 | - - |
Lethal congenital glycogen storage disease of heart Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 29, 2022 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Experimental studies have shown that this missense change affects PRKAG2 function (PMID: 27573176). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PRKAG2 protein function. ClinVar contains an entry for this variant (Variation ID: 6854). This missense change has been observed in individuals with PRKAG2-related cardiac conditions, including hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome (PMID: 18403758, 26085771, 27189955; Invitae). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 530 of the PRKAG2 protein (p.His530Arg). - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 11, 2021 | The p.H530R pathogenic mutation (also known as c.1589A>G), located in coding exon 15 of the PRKAG2 gene, results from an A to G substitution at nucleotide position 1589. The histidine at codon 530 is replaced by arginine, an amino acid with highly similar properties. This variant has been reported in individuals with hypertrophic cardiomyopathy (HCM), Wolff-Parkinson-White syndrome, and other cardiac arrhythmias, and it has been shown to segregate with disease in affected family members (Morita H et al. N Engl J Med, 2008 May;358:1899-908; Epicoco G et al. JACC Clin Electrophysiol, 2018 10;4:1377-1378; Aggarwal V et al. Ann Pediatr Cardiol;8:153-6; Xie C et al. Cell Res, 2016 Oct;26:1099-1111; Thevenon J et al. Europace, 2017 Apr;19:651-659; Lu C et al. J Transl Med, 2018 08;16:241). Functional studies in transgenic mouse models demonstrated consistent PRKAG2-related cardiac findings, including significant glycogen accumulation (Xie C et al. Cell Res, 2016 Oct;26:1099-1111). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
CardioboostCm
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;.;.
Eigen
Uncertain
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;.
MutationTaster
Benign
D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D
Sift4G
Pathogenic
D;T;D;D
Polyphen
P;.;.;.
Vest4
MutPred
Gain of MoRF binding (P = 0.0425);.;.;.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at